{"id":10242,"date":"2024-07-30T10:37:53","date_gmt":"2024-07-30T10:37:53","guid":{"rendered":"https:\/\/www.dhenne-avocats.fr\/?p=10242"},"modified":"2025-02-06T12:31:50","modified_gmt":"2025-02-06T12:31:50","slug":"sanofi-versus-amgen-success-of-the-first-legal-challenge-to-withdraw-a-patent-and-strict-evaluation-of-the-patentability-of-therapeutic-antibodies","status":"publish","type":"post","link":"https:\/\/www.dhenne-avocats.fr\/en\/sanofi-versus-amgen-success-of-the-first-legal-challenge-to-withdraw-a-patent-and-strict-evaluation-of-the-patentability-of-therapeutic-antibodies\/","title":{"rendered":"Sanofi vs. Amgen: Success of the first UPCA revocation action and strict assessment of the patentability of therapeutic antibodies"},"content":{"rendered":"<p>On 16 July 2024, the Munich Central Division revoked a patent for the first time as part of the dispute between Sanofi, Regeneron and Amgen.<a href=\"https:\/\/www.unified-patent-court.org\/en\/node\/922\">UPC_CFI_1\/2023<\/a>This decision is important not only because it is the first of its kind, but also because it establishes the JUB's position on the patentability of inventions relating to therapeutic antibodies.<\/p>","protected":false},"excerpt":{"rendered":"<p>Le 16 juillet 2024, la division centrale de Munich a r\u00e9voqu\u00e9 pour la premi\u00e8re fois un brevet dans le cadre du litige opposant Sanofi, Regeneron et Amgen (UPC_CFI_1\/2023).Cette d\u00e9cision est importante non seulement parce qu&rsquo;elle est la premi\u00e8re du genre, mais aussi parce qu&rsquo;elle \u00e9tablit la position de la JUB sur la brevetabilit\u00e9 des inventions [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16,7,28],"tags":[],"class_list":["post-10242","post","type-post","status-publish","format-standard","hentry","category-brevets","category-jub","category-pharmaceutique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques - Dhenne Avocats<\/title>\n<meta name=\"description\" content=\"Lisez l&#039;article : Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques du blog Dhenne Avocats\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dhenne-avocats.fr\/en\/sanofi-versus-amgen-success-of-the-first-legal-challenge-to-withdraw-a-patent-and-strict-evaluation-of-the-patentability-of-therapeutic-antibodies\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques - Dhenne Avocats\" \/>\n<meta property=\"og:description\" content=\"Lisez l&#039;article : Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques du blog Dhenne Avocats\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dhenne-avocats.fr\/en\/sanofi-versus-amgen-success-of-the-first-legal-challenge-to-withdraw-a-patent-and-strict-evaluation-of-the-patentability-of-therapeutic-antibodies\/\" \/>\n<meta property=\"og:site_name\" content=\"Dhenne Avocats\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-30T10:37:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-06T12:31:50+00:00\" \/>\n<meta name=\"author\" content=\"Matthieu DHENNE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Matthieu DHENNE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\"},\"author\":{\"name\":\"Matthieu DHENNE\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/person\\\/cebb642899b1d41301d41a0187fa329c\"},\"headline\":\"Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques\",\"datePublished\":\"2024-07-30T10:37:53+00:00\",\"dateModified\":\"2025-02-06T12:31:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\"},\"wordCount\":92,\"publisher\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\"},\"articleSection\":[\"Brevets\",\"JUB\",\"Pharmaceutique\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\",\"name\":\"Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques - Dhenne Avocats\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#website\"},\"datePublished\":\"2024-07-30T10:37:53+00:00\",\"dateModified\":\"2025-02-06T12:31:50+00:00\",\"description\":\"Lisez l'article : Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques du blog Dhenne Avocats\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\",\"name\":\"Dhenne Avocats\",\"description\":\"Cabinet d&#039;avocats en droit des brevets\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\",\"name\":\"Dhenne Avocats\",\"alternateName\":\"dhenne avocats\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png\",\"contentUrl\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png\",\"width\":512,\"height\":512,\"caption\":\"Dhenne Avocats\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/person\\\/cebb642899b1d41301d41a0187fa329c\",\"name\":\"Matthieu DHENNE\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"caption\":\"Matthieu DHENNE\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi vs. Amgen: Success of the first UPC revocation action and strict assessment of the patentability of therapeutic antibodies - Dhenne Avocats","description":"Read the article: Sanofi vs. Amgen: Success of the first UPJ revocation action and strict assessment of the patentability of therapeutic antibodies from the Dhenne Avocats blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dhenne-avocats.fr\/en\/sanofi-versus-amgen-success-of-the-first-legal-challenge-to-withdraw-a-patent-and-strict-evaluation-of-the-patentability-of-therapeutic-antibodies\/","og_locale":"en_GB","og_type":"article","og_title":"Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques - Dhenne Avocats","og_description":"Lisez l'article : Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques du blog Dhenne Avocats","og_url":"https:\/\/www.dhenne-avocats.fr\/en\/sanofi-versus-amgen-success-of-the-first-legal-challenge-to-withdraw-a-patent-and-strict-evaluation-of-the-patentability-of-therapeutic-antibodies\/","og_site_name":"Dhenne Avocats","article_published_time":"2024-07-30T10:37:53+00:00","article_modified_time":"2025-02-06T12:31:50+00:00","author":"Matthieu DHENNE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Matthieu DHENNE","Estimated reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/#article","isPartOf":{"@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/"},"author":{"name":"Matthieu DHENNE","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c"},"headline":"Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques","datePublished":"2024-07-30T10:37:53+00:00","dateModified":"2025-02-06T12:31:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/"},"wordCount":92,"publisher":{"@id":"https:\/\/www.dhenne-avocats.fr\/#organization"},"articleSection":["Brevets","JUB","Pharmaceutique"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/","url":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/","name":"Sanofi vs. Amgen: Success of the first UPC revocation action and strict assessment of the patentability of therapeutic antibodies - Dhenne Avocats","isPartOf":{"@id":"https:\/\/www.dhenne-avocats.fr\/#website"},"datePublished":"2024-07-30T10:37:53+00:00","dateModified":"2025-02-06T12:31:50+00:00","description":"Read the article: Sanofi vs. Amgen: Success of the first UPJ revocation action and strict assessment of the patentability of therapeutic antibodies from the Dhenne Avocats blog","breadcrumb":{"@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.dhenne-avocats.fr\/"},{"@type":"ListItem","position":2,"name":"Sanofi vs. Amgen : Succ\u00e8s de la premi\u00e8re action en r\u00e9vocation de la JUB et \u00e9valuation stricte de la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques"}]},{"@type":"WebSite","@id":"https:\/\/www.dhenne-avocats.fr\/#website","url":"https:\/\/www.dhenne-avocats.fr\/","name":"Dhenne Lawyers","description":"Patent law firm","publisher":{"@id":"https:\/\/www.dhenne-avocats.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dhenne-avocats.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.dhenne-avocats.fr\/#organization","name":"Dhenne Lawyers","alternateName":"dhenne avocats","url":"https:\/\/www.dhenne-avocats.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png","contentUrl":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png","width":512,"height":512,"caption":"Dhenne Avocats"},"image":{"@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c","name":"Matthieu DHENNE","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","caption":"Matthieu DHENNE"}}]}},"_links":{"self":[{"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/posts\/10242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/comments?post=10242"}],"version-history":[{"count":2,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/posts\/10242\/revisions"}],"predecessor-version":[{"id":10398,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/posts\/10242\/revisions\/10398"}],"wp:attachment":[{"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/media?parent=10242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/categories?post=10242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/tags?post=10242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}